Skip to main content
SpringerLink
Log in

Acid-Suppressive Effects of Various Regimens of Omeprazole in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Which Regimen Has the Strongest Effect?

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

To achieve more potent and long-lasting acid suppression, omeprazole was administered for 7 days in 5 regimens: 10, 20, and 40 mg once daily (od), and 10 and 20 mg twice daily (bid), in 7 healthy Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers, and intragastric pH was continuously measured. The median intragastric pH and percent time pH > 4.0 for 24 hours increased dose dependently with 10, 20, and 40 mg od. Ten and 20 mg bid wre comparable to 20 and 40 mg od, respectively. Concerning percent time pH > 4.0 in the nighttime (20:00–8:00 hours), 20 mg bid was significantly superior to 40 mg od (P < .05). In 4 of the 5 regimens, all 7 subjects had nocturnal acid breakthrough, whereas with 20 mg bid it occurred in only 3. We concluded that, considering nighttime acid suppression, omeprazole 20 mg bid had the strongest effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Sachs G, Wallmark B (1989) The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol (Suppl) 166:3–11

    CAS  Google Scholar 

  2. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S (1995) The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 35:277–305

    Article  PubMed  CAS  Google Scholar 

  3. Bate CM, Keeling PW, O’Morain C, Wilkinson SP, Foster DN, Mountford RA, Temperley JM, Harvey RF, Thompson DG, Davis M, Forgacs IC, Bassett KS, Richardson PDI (1990) Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31:968–972

    PubMed  CAS  Google Scholar 

  4. Porro GB, Pace F, Peracchia A, Bonavina L, Vigneri S, Scialabba A, Franceschi M (1992) Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 15:192–198

    Article  Google Scholar 

  5. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, Solcia E, Shearman DJ (1994) Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35:590–598

    PubMed  CAS  Google Scholar 

  6. Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenas E, Lundberg K (1994) Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 107:1305–1311

    PubMed  CAS  Google Scholar 

  7. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A, Plebani M, Davi G (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106–1110

    Article  PubMed  CAS  Google Scholar 

  8. Robertson D, Aldersley M, Shepherd H, Smith CL (1987) Patterns of acid reflux in complicated oesophagitis. Gut 28:1484–1488

    PubMed  CAS  Google Scholar 

  9. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, Rumi MA, Watanabe M, Kinoshita Y (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191–1196

    Article  PubMed  CAS  Google Scholar 

  10. Katz PO (2005) Review article: putting immediate-release proton-pump inhibitors into clinical practice—improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 22(Suppl 3):31–38

    Article  PubMed  CAS  Google Scholar 

  11. Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763–767

    Article  PubMed  CAS  Google Scholar 

  12. Peghini PL, Katz PO, Castell DO (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115:1335–1339

    Article  PubMed  CAS  Google Scholar 

  13. Ohara S, Kimpara T, Sekine H, Moriyama S, Kato K, Nakayama Y, Saito N, Sugiyama K, Asaki S, Toyota T (1995) Comparison of acid-inhibitory effect of omeprazole in before-breakfast dosing and after-breakfast dosing [in Japanese]. Jpn Pharmacol Ther 23:879–885

    Google Scholar 

  14. Kuo B, Castell DO (1996) Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 91:1532–1538

    PubMed  CAS  Google Scholar 

  15. Hatlebakk JG, Katz PO, Kuo B, Castell DO (1998) Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12:1235–1240

    Article  PubMed  CAS  Google Scholar 

  16. Orr WC, Harnish MJ (2003) The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 17:1553–1558

    Article  PubMed  CAS  Google Scholar 

  17. Wilder-Smith C, Halter F, Ernst T, Gennoni M, Zeyen B, Varga L, Roehmel JJ, Merki HS (1990) Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 4(Suppl 1):15–27

    PubMed  CAS  Google Scholar 

  18. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE (1990) Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 4(Suppl 1):29–45

    PubMed  CAS  Google Scholar 

  19. Smith JT, Gavey C, Nwokolo CU, Pounder RE (1990) Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 4(Suppl 1):47–63

    PubMed  CAS  Google Scholar 

  20. Rogers MJ, Holmfield JH, Primrose JN, Johnston D (1990) The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin. Aliment Pharmacol Ther 4(Suppl 1):65–74

    PubMed  CAS  Google Scholar 

  21. Nwokolo CU, Sawyerr A, Smith JT, Pounder RE (1990) Intravenous pentagastrin can induce the illusion of ‘tolerance’ to a single dose of an H2-blocker in man. Aliment Pharmacol Ther 4(Suppl 1):75–83

    PubMed  CAS  Google Scholar 

  22. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS (1990) Tolerance to oral H2-receptor antagonists. Dig Dis Sci 35:976–983

    Article  PubMed  CAS  Google Scholar 

  23. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552–561

    Article  PubMed  CAS  Google Scholar 

  24. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M (2003) Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 18:1149–1157

    Article  PubMed  CAS  Google Scholar 

  25. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–460

    Article  PubMed  CAS  Google Scholar 

  26. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T; Study Group of GERD (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965–973

    Article  PubMed  CAS  Google Scholar 

  27. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158–168

    Article  PubMed  CAS  Google Scholar 

  28. Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M (2003) Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 15:27–33

    Article  PubMed  CAS  Google Scholar 

  29. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598

    PubMed  CAS  Google Scholar 

  30. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  CAS  Google Scholar 

  31. Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661–666

    Article  PubMed  CAS  Google Scholar 

  32. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 24:270–276

    PubMed  CAS  Google Scholar 

  33. Naesdal J, Bodemar G, Walan A (1984) Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 19:916–922

    PubMed  CAS  Google Scholar 

  34. Howden CW, Forrest JA, Reid JL (1984) Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 25:707–710

    PubMed  CAS  Google Scholar 

  35. Olbe L, Cederberg C, Lind T, Olausson M (1989) Effect of omeprazole on gastric acid secretion and plasma gastrin. J Gastroenterol Hepatol 4(Suppl 2):19–25

    PubMed  Google Scholar 

  36. Nakashima M, Kanamaru M, Hashimoto H, Takiguchi Y, Mizuno A, Kajiho H, Oka T, Matsuda Y (1988) Phase I study of omeprazole-single-dose and multiple-dose studies [in Japanese]. Jpn J Clin Pharmacol Ther 19:667–679

    CAS  Google Scholar 

  37. Andersson T, Andren K, Cederberg C, Heggelund A, Lundborg P, Rohss K (1990) Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seven days of treatment. Drug Invest 2:184–188

    Google Scholar 

  38. Howden CW (1991) Clinical pharmacology of omeprazole. Clin Pharmacokinet 20:38–49

    PubMed  CAS  Google Scholar 

  39. Stedman CA, Barclay ML (2000) Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

    Tomohiko Shimatani & Susumu Tazuma

  2. Department of Geriatric Health Sciences, Graduate School of Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan

    Tomoko Kuroiwa, Mutsuko Moriwaki & Jing Xu

  3. Department of Internal Medicine, Hiroshima Prefectural Akitsu Hospital, 4388 Mitsu, Akitsu-cho, 729-2402, Higashi-Hiroshima, Japan

    Masaki Inoue

Authors
  1. Tomohiko Shimatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoko Kuroiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mutsuko Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susumu Tazuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaki Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimatani, T., Kuroiwa, T., Moriwaki, M. et al. Acid-Suppressive Effects of Various Regimens of Omeprazole in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Which Regimen Has the Strongest Effect?. Dig Dis Sci 52, 2826–2832 (2007). https://doi.org/10.1007/s10620-006-9643-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9643-x

Keywords

Search

Navigation